AI-created 'super vaccine' successfully tested on humans

Scientists have harnessed artificial intelligence (AI) to develop a brand-new type of "super vaccine," a breakthrough that could open new frontiers in medical science for combating future pandemics.

Researchers claim that for the first time in world history, the core component of a vaccine has been designed entirely by AI rather than humans—and has now been successfully tested on human subjects, reports BBC.

The vaccine was developed by a team of researchers at the University of Cambridge in the UK. Their goal is to create a vaccine that provides robust protection not just against current viruses, but also against future coronaviruses and other animal-borne pandemics that have yet to emerge.

Getting ahead of the virus
Conventional vaccines are typically designed to target existing variants or strains of a virus. However, viruses like coronavirus or influenza mutate rapidly, causing vaccine efficacy to wane over time and requiring updated versions to be formulated.

According to the researchers, the philosophy behind this new technology is not to chase after mutations, but to be prepared ahead of the virus.

"We are always lagging behind the virus," said Professor Jonathan Heeney of the University of Cambridge. "Our goal is to stay ahead of time, so that we can protect people before a new pandemic even spreads."

To achieve this, researchers first collected genetic data from various coronaviruses. The AI then analyzed this data to design a "super-antigen" capable of training the human immune system to recognize and fight off multiple mutations of the virus.

An antigen is the component of a vaccine that teaches the immune system how to identify a virus. Scientists claim that this AI-designed antigen can establish an effective defense against future viral mutations.

Human trials and current progress
Phase 1 Trials: The vaccine has already been tested on 39 volunteers to verify its safety and efficacy.

Phase 2 Trials: Trials are currently underway with approximately 200 participants.

The findings of this study have been published in the Journal of Infection. The report notes that while the immediate impact on the immune system remains at a "moderate" level, the overall results are highly promising.

Future scope: from bird flu to cancer
The researchers are already utilizing the same AI technology to run trials for a universal influenza vaccine and a vaccine against H5N1 bird flu. Work is also underway to develop vaccines for Ebola and other hemorrhagic fevers. Currently, certain strains of Ebola are spreading in the Democratic Republic of Congo for which no effective vaccine yet exists.

Professor Saul Faust from the University of Southampton believes that this AI-driven technology could play a crucial role in preventing both cancer and future pandemics.

Meanwhile, Professor Andy Pollard, Director of the Oxford Vaccine Group, noted that while this AI-based approach has shown incredibly powerful results in animal studies, the ultimate test will be proving its long-term efficacy and safety in humans.

Professor Marian Knight, Scientific Director at the National Institute for Health and Care Research (NIHR), hailed the achievement as groundbreaking. She stated that the AI-designed "super-antigen" opens up new possibilities for providing long-term, broad-spectrum viral protection.